These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Clinical pharmacology of anticancer agents [Part 5] Antimetabolites (2)]. Nakamura T; Ueda T; Uchida M Gan To Kagaku Ryoho; 1992 Mar; 19(3):409-20. PubMed ID: 1543370 [TBL] [Abstract][Full Text] [Related]
3. Pemetrexed: a multitargeted antifolate (ALIMTA, LY-231514). Jones RJ; Twelves CJ Expert Rev Anticancer Ther; 2002 Feb; 2(1):13-22. PubMed ID: 12113062 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of DNA synthesis in selection of anticancer therapy. Silvestrini R; Sanfilippo O; Daidone MG; Zaffaroni N Prog Clin Biol Res; 1988; 276():93-103. PubMed ID: 3174685 [No Abstract] [Full Text] [Related]
5. [New oral anticancer drug, TS-1 (S-1)--from bench to clinic]. Shirasaka T; Tsukuda M; Inuyama Y; Taguchi T Gan To Kagaku Ryoho; 2001 Jun; 28(6):855-64. PubMed ID: 11432358 [TBL] [Abstract][Full Text] [Related]
6. [Timeline from discovery of 5-FU to development of an oral anticancer agent S-1 and its drug concept]. Shirasaka T; Taguchi T Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():4-18. PubMed ID: 16897967 [TBL] [Abstract][Full Text] [Related]
7. Kinetic simulation of anticancer drug effects on metabolic pathway fluxes: two case studies. Jackson RC Bull Math Biol; 1986; 48(3-4):337-51. PubMed ID: 3828562 [No Abstract] [Full Text] [Related]
8. [Basic principles and clinical pharmacology of cytostatic treatment]. Schmidt CG Verh Dtsch Ges Inn Med; 1980; 86():337-67. PubMed ID: 7223027 [No Abstract] [Full Text] [Related]
9. Preface: oncometabolism: a new field of research with profound therapeutic implications. Galluzzi L; Kroemer G Methods Enzymol; 2014; 542():xix-xxiii. PubMed ID: 24862280 [No Abstract] [Full Text] [Related]
10. New Compound Targets Warburg Effect. Cancer Discov; 2015 Sep; 5(9):898. PubMed ID: 26209538 [No Abstract] [Full Text] [Related]
11. Determinants of response to antimetabolites and their modulation by normal purine and pyrimidine metabolites. Rustum YM; Danhauser L; Luccioni C; Au JL Cancer Treat Rep; 1981; 65 Suppl 3():73-82. PubMed ID: 7049369 [TBL] [Abstract][Full Text] [Related]
12. Clinical chronotolerance to anticancer drugs: relevance for dose-intensity. Bjarnason GA In Vivo; 1995; 9(6):557-64. PubMed ID: 8726802 [TBL] [Abstract][Full Text] [Related]
13. Application of NMR spectroscopy in biochemical studies of tumor cells sensitive and resistant to anticancer drugs. Hanusovská E; Dovinová I; Tkác I; Novotný L Neoplasma; 1998; 45(4):187-97. PubMed ID: 9890660 [TBL] [Abstract][Full Text] [Related]
14. [Methotrexate-leucovorin rescue therapy: pharmacological characteristics and clinical effective use]. Fujimoto T Gan To Kagaku Ryoho; 1996 Dec; 23(14):1901-6. PubMed ID: 8978794 [TBL] [Abstract][Full Text] [Related]
15. Cytotoxic anticancer agents and renal impairment study: the challenge remains. Rahman A; White RM J Clin Oncol; 2006 Feb; 24(4):533-6. PubMed ID: 16391294 [No Abstract] [Full Text] [Related]
17. An overview of folate metabolism: features relevant to the action and toxicities of antifolate anticancer agents. Calvert H Semin Oncol; 1999 Apr; 26(2 Suppl 6):3-10. PubMed ID: 10598549 [No Abstract] [Full Text] [Related]